The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Sema4
Analysis of real-world data (RWD) on treatment (tx) sequencing in patients with advanced non-small cell lung cancer (aNSCLC).
 
Meng Ma
Employment - Sema4
 
Xiang Zhou
Employment - SEMA4
 
Howard Goldsweig
Employment - Sema4
 
Nicholas Hahner
Employment - Sema4
 
Dianwei Han
Employment - Sema4
 
Matthew Dietz
Employment - Sema4
 
Scott Jones
Employment - Sema4
 
Tommy Mullaney
Employment - Sema4
Stock and Other Ownership Interests - Sema4
 
Arielle Redfern
Employment - Sema4
 
Whitney Jappe
Employment - Sema4
Stock and Other Ownership Interests - COTA
 
Zongzhi Liu
Employment - Sema4
 
Kamlesh Yadav
Employment - Sema4
 
Michelle Zimmerman
No Relationships to Disclose
 
Tony Prentice
Employment - Sema4
Leadership - Sema4
Stock and Other Ownership Interests - Sema4
 
Qi Pan
Employment - Boehringer Ingelheim; Genscript; Sema4
Leadership - Boehringer Ingelheim; Genscript; Sema4
Stock and Other Ownership Interests - Genscript; Sema4
Consulting or Advisory Role - Adlai Nortye; Simcere
Patents, Royalties, Other Intellectual Property - Boehringer Ingelheim; Genscript
Travel, Accommodations, Expenses - Sema4
 
Fred R. Hirsch
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Genentech; HTG Molecular Diagnostics; Lilly; Merck; Pfizer; Roche; Ventana Medical Systems
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Lilly/ImClone (Inst)
Patents, Royalties, Other Intellectual Property - EGFR FISH and IHC for prediction of outcome in patients treated with EGFR inhibitors (Inst)
 
William K. Oh
Leadership - checkpoint Sciences
Stock and Other Ownership Interests - Bellicum Pharmaceuticals
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; checkpoint Sciences; Churchill Pharmaceuticals; Dendreon; Inovio Pharmaceuticals; Janssen; Sanofi; Sema4; TYME
Research Funding - Sotio (Inst)
 
Eric E. Schadt
Employment - Sema4
Leadership - Sema4
Stock and Other Ownership Interests - Sema4
 
Dan Li
Employment - Pacira Pharmaceuticals (I); Sema4; Symphogen (I)
Stock and Other Ownership Interests - Sema4
 
Rong Chen
Employment - Sema4
Stock and Other Ownership Interests - Personalis; Sema4
Consulting or Advisory Role - Roche
Research Funding - Boehringer Ingelheim
Patents, Royalties, Other Intellectual Property - Personalis; Quest Diagnosis
Travel, Accommodations, Expenses - Roche